Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type I collagen alpha-2 chain is one of the two unique polypeptide chains that assemble into the triple helix structure of type I collagen, the most abundant fibrillar collagen in the human body[1][2][3][5][7]. Synthesized from the COL1A2 gene, this chain combines with two alpha-1 chains (encoded by COL1A1) to form mature type I collagen fibers that provide structural support and tensile strength to connective tissues such as bone, tendon, skin, and the sclera. Mutations in the COL1A2 gene disrupt collagen synthesis or fiber assembly, resulting in connective tissue disorders—most notably various forms of osteogenesis imperfecta and certain subtypes of Ehlers-Danlos syndrome, which are characterized by bone fragility, joint hypermobility, and sometimes cardiovascular involvement[1][3][5]. The Type I collagen alpha-2 chain is classified as a structural extracellular matrix protein and is not a receptor, enzyme, transporter, or a typical druggable target. There are currently no approved therapies that directly target the COL1A2 protein or gene, but its mutations serve as important diagnostic biomarkers for associated connective tissue diseases[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type I collagen alpha-2 chain (COL1A2).